Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Intensity Therapeutics Inc

INTS ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.90

▲ +3.05%

Market Cap $15.98M · Vol 4.92K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$15.98M

Micro Cap

Div Yield

N/A

EPS Growth

+53.30%

YoY

RSI (14)

69.15

Momentum

Beta

N/A

vs Market

52W High

$43.25

88.68% below

52W Low

$3.52

39.06% above

Volume

4.92K

Avg 5.89K

P/B

0.09

Price-to-book

ROE

N/A

Return on equity

Free Float

96.08%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Intensity Therapeutics Inc (INTS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INTS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+16.27%

+9.75%

+3.93%

-31.25%

YTD

-52.27%

-37.22%

-96.71%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-11,606,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-122.92% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.09
P/FCF	N/A
EPS Growth	+53.30%
Outstanding Shares	3.26M

Technical Indicators

50-Day SMA	$4.35
200-Day SMA	$6.88
RSI (14)	69.15
Beta	N/A
52-Week High	$43.25
52-Week Low	$3.52

Volume Today	4.92K
Avg Daily Volume (30D)	5.89K
Relative Volume	0.83x
Volatility (10D)	80.25
Volatility (30D)	62.09
Free Float	96.08%

Analyst Consensus

BUY

Current Price $4.90

Mean Target $17.20

52W Low$3.52 52W High$43.25

Current

Target

$3.52 $43.25

Current Analyst target

+251.38% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00B57FZW5

ISINUS45828J2024

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.02% ONC BeOne Medicines AG +1.18% RVMD Revolution Medicines Inc -0.09% 068270.KS Celltrion Inc -2.27% ABVX Abivax SA +1.53%

Company Profile

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.